Evidence map›Paper›PMID 28446674›Full record

ArticleJournal of virology2017

Broadening CD4

Jonathan Filskov, Marianne Mikkelsen, Paul R Hansen, Jan P Christensen, Allan R Thomsen, Peter Andersen, Jens Bukh, Else Marie Agger

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. CD8iScience · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Peptides for Vaccine Development.ACS applied bio materials · 2022
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jonathan FilskovCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark.
Marianne MikkelsenCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark.
Paul R HansenDepartment of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Jan P ChristensenDepartment of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Allan R ThomsenDepartment of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Peter AndersenDepartment of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.
Jens BukhCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark jbukh@sund.ku.dk.
Else Marie AggerDepartment of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.
Statens Serum Institut · DKUniversity of Copenhagen · DKCopenhagen University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the introduction of effective drugs to treat patients with chronic hepatitis C virus (HCV) infection, a vaccine would be the only means to substantially reduce the worldwide disease burden. An incomplete understanding of how HCV interacts with its human host and evades immune surveillance has hampered vaccine development. It is generally accepted that in infected individuals, a narrow repertoire of exhausted T cells is a hallmark of persistent infection, whereas broad, vigorous CD4

Indexed as

Adjuvants, ImmunologicAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCross-PrimingCytotoxicity, ImmunologicDEAD-box RNA HelicasesEpitopesHepatitis CInterferon-gammaLiposomesMiceNucleoside-TriphosphataseSerine EndopeptidasesTumor Necrosis Factor-alphaVaccines, SubunitAdjuvants, ImmunologicDEAD-box RNA HelicasesEpitopesInterferon-gammaLiposomesNS3 protein, hepatitis C virusNucleoside-TriphosphataseSerine EndopeptidasesTumor Necrosis Factor-alphaVaccines, SubunitViral Nonstructural ProteinsViral ProteasesViral Vaccinescellular immunityHCVhepaciviruseshepatitishepatitis C virusvaccine

Identifiers

PMID28446674
PMCPMC5487548
OpenAlexW2608500216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.